Measuring intratumoral vessel density using automated image analysis
Digital image analysis to analyse the intratumoral vessel density within specified regions of resected colon and TMA sections of colon tumour.
A stromal cell population that inhibits adipogenesis in mammalian fat depots
Adipocyte development and differentiation play an important role in the origin of obesity and many related diseases such as type 2 diabetes and cancer. Using a single-cell transcriptomics-based approach in a mouse model revealed three different adipocyte progenitor cell populations, including one subpopulation, termed Aregs, that suppressed adipocyte formation in vitro and in vivo.
Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples
Upregulation of PD-L1 is associated with increased risk and tumourigenicity of cancers, helping many escape immune surveillance. PD-1/PD-L1 expression has been suggested as a possible biomarker for identifying patients that may be sensitive to PD1/PD-L1 immunotherapies. Current PD1/PD-L1 testing procedures may not be sufficient to distinguish responders and this study aimed to simplify the process by assessing the different methods on clinically-relevant NSCLC samples, to identify factors relevant for PD-L1 detection and make assays more robust and reproducible.
Antibody Validation: Does the antibody really recognise what it says on the label?
Epistem has an expert histology lab whose capabilities are available as a standalone service, or integrated to add value to your preclinical model. Nicola Tonge, Epistem's Histology Manager and IHC specialist discusses the issues faced when choosing the correct antibody as there is currently no industry standard for antibody validation, and not all antibodies work 'how they say on the label'.
Multiplexing Immunohistochemistry: A new method for integrating biomarker expression
Multiplexed biomarkers and diagnostics can provide a greater understanding of the response of a tissue to a drug, or of disease stage, allowing further progress towards personalised medicines.